Tag:

Boehringer Ingelheim

Latest Headlines

Latest Headlines

Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF

When it comes to the makings of a market-share showdown, the idiopathic pulmonary fibrosis (IPF) landscape has it all. Same-day FDA approvals? Check. A patient population never before reached by pharma? Check. Nearly identical price tags? As of this week, that's a check, too.

Same-day approvals send Roche, Boehringer to IPF market battle

There's nothing like same-day FDA approvals to trigger a market showdown--and that's the case for a pair of new idiopathic pulmonary fibrosis (IPF) treatments. After snagging nods from the agency Wednesday, Roche's Esbriet and Boehringer Ingelhem's Ofev will be going head-to-head.

InterMune and Boehringer win tandem FDA nods for 'breakthrough' lung drugs

InterMune and Boehringer Ingelheim have spent the last year or so jockeying for the spotlight with in-development treatments for a rare lung disease, hoping to take pole position upon reaching the market. Now, as the FDA has decided to approve both drugs at once, the two companies will set off from equal starting points in the race for dominance.

Boehringer pilots inhalers with sensors to encourage patient adherence

Boehringer Ingelheim envisions some day selling day a smart inhaler that can tell patients when its medication is running low and remind them if they missed a prescheduled dose. 

Boehringer to invest a further $19M in German plant expansion

Boehringer Ingelheim has added a subproject to the expansion of its Respimat production plant in Dortmund, Germany.

EU panel backs slew of new drugs and uses, boosting Lilly, AZ, Novartis, Gilead and more

When Europe's drug approval gatekeepers meet, they often tick off recommendations for some key Big Pharma products. This week, the Committee for Medicinal Products for Human Use backed a whopping 15 new meds and 3 new indications.

FDA's Mini-Sentinel set to graduate on October 1

The FDA's Mini-Sentinel has long since outgrown its "mini" moniker and is now ready to graduate from being a pilot project to being an integral part of the agency's drug-safety infrastructure. Many people welcome the program's progress, but doubts and dissenting voices remain.

Faltering Boehringer slashes 600 jobs in Germany in bid to save $580M

The bloodletting in Big Pharma continues with news today that Boehringer Ingelheim is planning between 500 and 600 job cuts in its home country of Germany. The cuts come just a few weeks after the company announced its sales had dropped 3% in the first 6 months of the year and full-year results would likely be down slightly from last year.

Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac

A little more than two months after inking a licensing deal with Sanofi, CureVac has completed another tie-up, banking a $45 million upfront from Boehringer Ingelheim and partnering its therapeutic vaccine aimed at lung cancer. The deal also includes up to about $556 million in prospective milestones for the German biotech.

Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice

Eli Lilly and Boehringer Ingelheim won European clearance for their biosimilar of Lantus, Sanofi's top-selling insulin product, but the treatment's full potential remains hamstrung by a U.S. patent challenge.